Table 2. Major serotypes and associations with resistance among Streptococcus pneumoniae from the British Society for Antimicrobial Chemotherapy Respiratory Surveillance, United Kingdom and Republic of Ireland, 2013/14 and 2014/15 (n=805).
| Serotype | October 2013 to September 2014 | October 2014 to September 2015 | ||||
|---|---|---|---|---|---|---|
| Count | % of total isolates | No (%) with triple resistance | Count | % of total isolates | No (%) with triple resistance | |
| 15A | 34 | 9.1 | 13 (38.2%) | 46 | 10.7 | 22 (47.8%) |
| 23B | 26 | 6.9 | 1 (3.8%) | 21 | 4.9 | 0 |
| 3 | 22 | 5.9 | 0 | 26 | 6.0 | 0 |
| 11A | 21 | 5.6 | 1 (4.8%) | 34 | 7.9 | 1 (2.9%) |
| 23A | 21 | 5.6 | 0 | 30 | 7.0 | 4 (13.3%) |
| 22F | 19 | 5.1 | 0 | 17 | 4.0 | 0 |
| 6C | 18 | 4.8 | 0 | 12 | 2.8 | 0 |
| 19A | 17 | 4.5 | 5 (29.4%) | 14 | 3.3 | 4 (28.6%) |
| 24F | 16 | 4.3 | 0 | 12 | 2.8 | 1 (8.3%) |
| 35F | 14 | 3.7 | 0 | 14 | 3.3 | 0 |
| 10A | 14 | 3.7 | 0 | 12 | 2.8 | 0 |
| 31 | 14 | 3.7 | 0 | 16 | 3.7 | 0 |
| 16F | 12 | 3.2 | 1 (8.3%) | 19 | 4.4 | 0 |
| 15B | 11 | 2.9 | 0 | 3 | 0.7 | 0 |
| 17F | 11 | 2.9 | 0 | 16 | 3.7 | 0 |
| 19F | 11 | 2.9 | 3 (27.3%) | 14 | 3.3 | 5(35.7%) |
| 35B | 11 | 2.9 | 0 | 18 | 4.2 | 0 |
| 8 | 10 | 2.7 | 0 | 12 | 2.8 | 1 (8.3%) |
| Other serotypes, with < 10 isolates in one or both years | 73 | 19.4 | 3 (4.9%)a | 85 | (21.7) | 10 (2.3%)a |
| PCV7 serotypes | 17 | 4.5 | NA | 20 | 4.6 | NA |
| PCV13 serotypes | 63 | 16.8 | NA | 67 | 15.6 | NA |
| Total | 375 | 100 | 27 (7.2%) | 430 | 100 | 49 (11.4%) |
NA: not applicable; PCV: pneumococcal conjugate vaccine.
a In 2013/14, three 6B isolates had triple resistance; the 10 'Other serotype' isolates with triple resistance in 2014/15 comprised three non-typeable, two 12F and single representatives of 6B, 7F, 9N 9V and 23.